Dexcom Q4 revenue $815.2M (+17% YoY); G7 CGM FDA cleared; guides 2023 rev $3.35-3.49B

DEXCOM INC

2022-FY EPS reported $0.82 revenue$2,909,800,000

Q4 2022 revenue $815.2M (+17% reported, +20% organic); U.S. +17%, international +15% (organic +27%).
GAAP operating income $125.4M (15.4% margin) vs $0.6M in Q4 2021; non-GAAP operating income $172.1M (21.1% margin).
GAAP EPS $0.22 diluted; non-GAAP EPS $0.34 diluted; cash & marketable securities $2.46B.
FDA cleared Dexcom G7 CGM for ages 2+; rollout in U.S. market in 2023.
FY2023 guidance: revenue $3.35-3.49B (15-20% growth); non-GAAP gross margin 62-63%; non-GAAP op margin ~16.5%; Adj. EBITDA margin ~26%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DEXCOM INC updated its quarter and year ended December 31, 2022 guidance (reaffirmed).

Period: quarter and year ended December 31, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the quarter and year ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DEXCOM INC filing history →

Source: SEC EDGAR

accession 0001093557-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.